<DOC>
	<DOCNO>NCT00075335</DOCNO>
	<brief_summary>Peripheral blood progenitor cell ( PBPC ) become preferred source hematopoetic stem cell allogeneic transplantation technical ease collection short time require engraftment . Traditionally , granulocyte-colony stimulating factor ( G-CSF ) use procure peripheral blood stem cell graft . Although regimen use G-CSF usually succeed collect adequate number PBPC healthy donor , 5 % -10 % mobilize stem cell poorly may require multiple large volume apheresis bone marrow harvest . Although G-CSF generally well tolerate healthy donor , may associate bone pain , headache , myalgia rarely life threaten side effect like stroke , myocardial infarction splenic rupture . AMD3100 , bicyclam compound inhibit bind stromal cell derive factor-1 ( SDF-1 ) cognate receptor CXCR4 . CXCR4 present CD34+ hematopoetic progenitor cell interaction SDF-1 play pivotal role home CD34+ cell bone marrow . Inhibition CXCR4-SDF1 axis AMD3100 release CD34+ cell circulation , collect easily apheresis . Recently , publish report demonstrate large number CD34+ cell rapidly mobilize healthy volunteer follow single subcutaneous injection AMD3100 . Remarkably , number CD34+ cell collect apheresis follow single injection AMD3100 comparable number CD34+ cell collect historical control receive 5 day G-CSF prior stem cell mobilization . Although study population relatively small , side-effects agent mild transient serious complication report . The ability collect large quantity PBPC single injection drug make attractive agent mobilize donor allogeneic PBPC . However , immunologic profile AMD3100 mobilize cell , term lymphocyte content ( T cell , B cell , NK cell , immuno-regulatory T cell ) , T cell polarization status ( TH1 versus TH2 ) , status antigen present cell ( DC1 versus DC2 ) , alloreactive potential , preservation reactivity infectious agent ( e.g . EBV , CMV ) unknown . Consequently , whether AMD3100 mobilize PBPC would suitable use allograft uncertain . In study collect PBPCs follow single subcutaneous injection AMD3100 healthy donor previously PBPC collect use standard G-CSF mobilization . The AMD3100 mobilize cell , G-CSF mobilize cell , circulate cell prior AMD3100 G-CSF mobilization analyze term cellular content function lymphocytes , NK cell , antigen present cell . AMD3100 mobilize PBPC collect purpose research study use therapeutic purpose .</brief_summary>
	<brief_title>AMD3100 Mobilize Stem Cells Donation</brief_title>
	<detailed_description>Peripheral blood progenitor cell ( PBPC ) become preferred source hematopoietic stem cell allogeneic transplantation technical ease collection short time require engraftment . Traditionally , granulocyte-colony stimulating factor ( G-CSF ) use procure peripheral blood stem cell graft . Although regimen use G-CSF usually succeed collect adequate number PBPC healthy donor , 5 % -10 % mobilize stem cell poorly may require multiple large volume apheresis bone marrow harvest . Although G-CSF generally well tolerate healthy donor , may associate bone pain , headache , myalgia rarely life threaten side effect like stroke , myocardial infarction splenic rupture . AMD3100 bicyclam compound inhibit bind stromal cell derive factor-1 ( SDF-1 ) cognate receptor CXCR4 . CXCR4 present CD34+ hematopoietic progenitor cell interaction SDF-1 play pivotal role home CD34+ cell bone marrow . Inhibition CXCR4-SDF1 axis AMD3100 release CD34+ cell circulation , collect easily apheresis . Recently , publish report demonstrate large number CD34+ cell rapidly mobilize healthy volunteer follow single subcutaneous injection AMD3100 . Remarkably , number CD34+ cell collect apheresis follow single injection AMD3100 comparable number CD34+ cell collect historical control receive 5 day G-CSF prior stem cell mobilization . Although study population relatively small , side-effects agent mild transient serious complication report . The ability collect large quantity PBPC single injection drug make attractive agent mobilize donor allogeneic PBPC . However , immunologic profile AMD3100 mobilize cell , term lymphocyte content ( T cell , B cell , NK cell , immuno-regulatory T cell ) , T cell polarization status ( TH1 versus TH2 ) , status antigen present cell ( DC1 versus DC2 ) , alloreactive potential , preservation reactivity infectious agent ( e.g . EBV , CMV ) unknown . Consequently , whether AMD3100 mobilize PBPC would suitable use allograft uncertain . In study collect PBPCs follow single subcutaneous injection AMD3100 healthy donor previously PBPC collect use standard G-CSF mobilization . The AMD3100 mobilize cell , G-CSF mobilize cell , circulate cell prior AMD3100 G-CSF mobilization analyze term cellular content function lymphocytes , NK cell , antigen present cell . AMD3100 mobilize PBPC collect purpose research study use therapeutic purpose . The primary objective characterize cellular content immunological property AMD3100 mobilize PBPC donor previously go mobilization G-CSF , study safety efficacy peripheral blood stem cell mobilizer . The primary endpoint ratio Th1 ( intracellular IFN-gamma plus ) versus Th2 ( intracellular IL-4 plus ) T-cells apheresis product collect individual donor undergo G-CSF AMD3100 hematopoietic progenitor cell mobilization . Secondary endpoint include cellular content immune property AMD3100 mobilize cell yield hematopoietic progenitor cell , immune cell , cellular subset collect apheresis subject undergo G-CSF AMD3100 mobilization safety profile AMD3100 .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Mobilization collection PBPC use GCSF least 60 day prior protocol enrollment ( stem cell donor enrol Branch transplant protocols healthy volunteer enrol 96H0049 : Use granulocyte colony stimulate factor mobilize leukapheresis collection healthy volunteer ) . 2 . Ages great equal 18 year less equal 80 year . 3 . Normal renal function : creatinine le 1.5 mg/dl . 4 . Normal liver function : total bilirubin less than1.5mg/dl , ALT 6 41 U/L , AST 934 U/L . 5 . Normal blood count : WBC 300010000/mm ( 3 ) granulocyte great 1500/mm ( 3 ) platelet great than150,000/mm ( 3 ) hemoglobin ( female great 11.1 g/dl , male great 12.7 g/dl ) . 6 . Subject must eligible normal blood donation fit undergo apheresis procedure ( antecubital vein must adequate peripheral access apheresis ) . 7 . Ability comprehend investigational nature study provide inform consent . EXCLUSION CRITERIA : Any Following 1 . Active infection history recurrent infection hepatitis B C ( HBsAg , AntiHBc , AntiHCV ) , HIV HTLV1 . 2 . History autoimmune disease rheumatoid arthritis , systemic lupus erythematous . 3 . History cancer within past 5 year exclude basal cell squamous cell carcinoma skin . 4 . History hematologic disorder include thromboembolic disease . 5 . History cardiac disease uncontrolled hypertension , peripheral vascular disease , myocardial infarction , cardiac arrhythmia OR relate symptom tachycardia , chest pain , shortness breath require medical intervention OR treatment Framingham coronary disease risk prediction score great 10 % 10 year coronary heart disease ( CHD ) risk . 6 . History cerebrovascular disease , transient ischemic attack , stroke . 7 . Pregnant lactating . 8 . Severe psychiatric illness : mental deficiency sufficiently severe make informed consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hematopoietic Stem Cells</keyword>
	<keyword>Mobilization</keyword>
	<keyword>Alloreactivity</keyword>
	<keyword>T Cell Polarization</keyword>
	<keyword>Dendritic Cells</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Mozobil</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>